Podcasts about antibodies

In this episode of Rheuminations, host Adam J. Brown, MD, untangles the confusing serologies of lupus by learning about their discoveries from the beginning. He answers questions like what's the deal with immunofluorescence patterns, why does SSA/SSB have two names (Ro/LA), and is double-stranded DNA antibody really attracted to both strands? ·       The story of antibodies in lupus. 3:27 ·       The "LE" factor. 10:11 ·       The changing fluorescent patterns of the staining of the nucleus/ENAs. 18:50 ·       The anti-Smith antibody. 24:51 ·       The mysteries of SSA and SSB. 28:52 ·       Double-stranded DNA. 36:32 ·       Crithidia luciliae. 40:30  We'd love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum. References: Aarden LA, et al. Ann NY Acad Sci. 1975;doi:10.1111/j.1749-6632.1975.tb29197.x Alspaugh MA, et al. Arthritis Rheum. 1976;doi:10.1002/art.1780190214 Aslpaugh MA, et al. J Clin Invest. 1975;doi:10.1172/JCI108007 Arana R, et al. J Clin Invest. 1967;doi:10.1172/JCI105677 Clark G, et al. J Immunol. 1969;PMED:4179557 Dubois EL, et al. Blood. 1957;doi:10.1182/blood.V12.7.657.657 Friou GJ, et al. J Immunol. 1958;doi:10.4049/jimmunol.80.4.324 Hargraves MM. Proc Staff Meet Mayo Clin. 1949;doi:10.1016/S0025-6196(25)08519-2 Haserick JR, et al. Am J Med Sci. 1950;doi:10.1097/00000441-195006000-00010 Rowell NR, et al. Arch Dermatol. 1963;doi:10.1001/archderm.1963.01590200064012 Tan EM, et al. J Clin Invest. 1966;doi:10.1172/JCI105479 Tsokos GC. J Immunol. 2006;doi:10.4049/jimmunol.176.3.1295

Bristol Myers Squibb has selected Houston as the site for a new $2.3 billion multi-modal manufacturing campus designed to support drug product and finished goods manufacturing from late development through launch. Recursion, Roche, and its Genentech subsidiary have announced plans to co-develop a neuroscience discovery program based on the first validated target discovered through an AI map. Editors reminisce over the changes in science since the COVID-19 pandemic in light of a new large NIH-funded study that shows COVID-19 can reactivate dormant viruses, including Epstein-Barr and cytomegalovirus. In other infectious disease news, drug-resistant Candida auris was found to persist in hair follicles by exposing chitin, triggering interferon-γ that suppresses skin defenses and creates a niche for fungal colonization.Join GEN editors Corinna Singleman, PhD, Alex Philippidis, and Julianna LeMieux, PhD, for a discussion of the latest biotech and biopharma news. Listed below are links to the GEN stories referenced in this episode of Touching Base: BMS Chooses Houston for $2.3B Manufacturing FacilityBy Alex Philippidis, GEN Edge, Aug 10, 2026Next 10 U.S. Biopharma ClustersBy Alex Philippidis, GEN, Aug 12, 2026Recursion Partners with Genentech to Advance First Validated Neuro Target Discovered Through AI MapBy Alex Philippidis, GEN Edge, Aug 5, 2026COVID-19 Reactivates Dormant Viruses, Offering New Clues to Long COVIDGEN, Aug 5, 2026Trump's Treatments: Regeneron's Antibodies and Gilead's Remdesivir ExplainedBy Alex Philippidis, GEN, Oct 5, 2020Lessons from the COVID Crisis: An Interview with Peter HotezBy Alex Philippidis, GEN Edge, Oct 19, 2022How to Conquer Coronavirus: Top 35 Treatments in DevelopmentBy Alex Philippidis, GEN, March 2, 2020Candida auris Persists in Hair Follicles, Hijacks Immune SignalingGEN, August 10, 2026The State of Biotech SummitSeptember 23, 2026 Touching Base Podcast Hosted by Corinna Singleman, PhD Behind the Breakthroughs Hosted by Jonathan D. Grinstein, PhD The State of Biologics Testing 2026Charles River Laboratories and GEN, June 10, 2026Subscribe to GEN's newsletters Hosted on Acast. See acast.com/privacy for more information.

How have antibody trends changed over the decades? Janice Reichert, Ph.D., founder and editor-in-chief of mAbs, joins host Paul Carter, Ph.D., to discuss the evolution of monoclonal antibody therapeutics and their experiences with shaping—and documenting—the field. Their conversation covers the advances that have transformed the industry, evolving success rates for antibody therapeutics, and the growing sophistication of multispecific antibodies, antibody-drug conjugates, and more. Plus, they discuss both AI and China's emergence as major forces in antibody development. Links from this episode:  Genentech mAbs 

Labs read "normal" but you're gaining midsection weight, foggy and running at 70%? Your thyroid - not just perimenopause - may be the missing variable. Dr. Amie Hornaman explains why TSH alone misses the picture, how elevated reverse T3 "pools" and blocks T3 at the cell even when free T3 looks optimal, and why roughly 98% of women don't thrive on T4-only. She links falling progesterone, rising thyroid-binding globulin, low ferritin and the "thyropause" hitting 80-90% of women over 40. WHAT YOU'LL LEARN Why a "normal" TSH can completely miss a thyroid problem - and the five markers that actually reveal what's happening What reverse T3 "pooling" is, and how it blocks active thyroid hormone at the cell even when your free T3 looks optimal Why roughly 98% of women stop thriving on T4-only medication once they're past 40 How falling progesterone drives estrogen dominance, raises thyroid binding globulin, and quietly strands thyroid hormone before it reaches the cell What "thyropause" is, why it hits 80-90% of women over 40, and how it overlaps with the perimenopause symptoms you're blaming instead Why testosterone acts as armor against autoimmunity - and what its decline switches on How low ferritin, insulin resistance and cortisol compound thyroid-driven fatigue and stubborn belly fat TIMESTAMPS 00:00 - Intro: Why Midlife Women Go Undiagnosed & the Full Thyroid Panel Doctors Skip (TSH, Free T3/T4, Reverse T3, Antibodies)09:46 - Reverse T3 "Pooling," Why T4-Only Fails Most Women & What Actually Drives High Reverse T317:28 - How HRT, Progesterone Loss & Low Ferritin Hit Your Thyroid - Plus the "Thyropause" Switch22:09 - Core Thyroid Nutrients, Iodine Dosing Do's & Don'ts, and How to Actually Fix Low Iron40:14 - High Antibodies and Still Optimized? Hashimoto's Triggers & Protecting Your Thyroid45:40 - Midlife Belly Fat & Bloating: Root Causes, Smart Testing Order & the Gut-Healing Myth53:12 - Thyropause & Lean Athletes: Why Most Women Over 40 Get Hit - Plus The Thyroid Fix Book VALUABLE RESOURCES The Thyroid Fix (Dr. Amie's book) https://thyroidfixbook.com/ Dr. Amie Hornaman's website / book a call https://dramie.com/ Fixxr Supplements (Dr. Amie's line, incl. iodine) https://dramiehornaman.com/collections/supplements Follow Dr. Amie on Instagram https://www.instagram.com/dramiehornaman/ Thanks to my sponsor, Eight Sleep Sleep cooler, recover faster. The Eight Sleep Pod pre-cools your bed and adjusts all night for deeper sleep - dual-zone, so you and your partner each get your own temp.

Bispecific antibodies (BsAbs) continue to garner the interest of both academic and community cancer centers due to their rapid growth in FDA approvals and increasing use in hematologic malignancies and solid tumors. However, practical considerations such as treatment-related toxicities, choosing the right delivery model, and staffing constraints deter many programs from attempting to implement BsAbs. In this episode, CANCER BUZZ speaks with 2026 ACCC Innovator Award winner Kate Kennedy, MSN, APRN, ACNP-BC, AOCNP, an Outpatient Hematology Advanced Practice Provider (APP) Team Lead at Vanderbilt-Ingram Cancer Center, about her program's APP-led BsAb step-up dosing clinic. With APPs at the helm, this model enables efficient and specialty-expert management of therapies while optimizing physician resources. In addition, its adherence to step-up dosing protocols prioritizes patient safety and convenience while reducing inpatient resource utilization. "[It's important to look] at what you need to spend money on, [make] sure that you're spending money on the right things, and then [look] for areas like space and staff that maybe have capacity that you can utilize in a little bit of a different way to deliver this care." – Kathryn Kennedy, MSN, APRN, ACNP-BC, AOCNP Guest: Kathryn Kennedy, MSN, APRN, ACNP-BC, AOCNPOutpatient Hematology APP Team Lead Vanderbilt-Ingram Cancer Center Nashville, Tennessee Resources: ACCC 43rd National Oncology Conference 2026 ACCC Innovator Vanderbilt-Ingram Cancer Center Blog: An APP-Led Outpatient Bispecific Antibody Clinic Podcast: APPs Paving the Way in Leadership Blog: Maximizing the Role of APPs in Oncology Care Blog: Bispecific Antibodies Are Moving Forward; So Are the Implementation Questions  

On today's Good Day Health Show - ON DEMAND…Dr. Jack Stockwell, a NUCCA Chiropractor and GAPS Practitioner in SLC, UT (866.867.5070 | ForbiddenDoctor.com | JackStockwell.com), shares a holistic perspective on health news today. Dr. Jack offers an insightful discussion on recent developments in health policy and preventive medicine, including the value of comprehensive blood work, evolving COVID-19 vaccination recommendations, and the ongoing conversation surrounding cholesterol and heart health. Dr. Jack explains why looking beyond standard lab values can provide a more complete picture of overall wellness and explores concepts such as hybrid immunity, individualized healthcare, and informed decision-making. The episode also examines current discussions about vaccine safety, public health policy, and the importance of evaluating emerging research.Key Takeaways:Comprehensive blood testing can provide valuable insight into overall health beyond basic screening panels.Public health recommendations continue to evolve as new research becomes available.Individual health decisions are best made through informed discussions with qualified healthcare professionals.Cholesterol is one factor among many that contribute to cardiovascular health and should be evaluated within the broader context of overall risk.Staying informed and reviewing current scientific evidence can help individuals make thoughtful decisions about their health.For more on Good Day Health…Website: GoodDayHealthShow.comSocial Media: @GoodDayNetworks

As bispecific antibodies (BsAbs) become more integrated into oncology care, much of the focus has been placed on clinical protocols and operational readiness. However, less attention has been paid to the patient and caregiver experience. In this episode, CANCER BUZZ explores how it feels physically and emotionally for patients to begin and continue BsAb therapy. Grounded in real-world insights, this discussion highlights the logistical and emotional challenges that arise during the step-up period and early treatment phases and identifies opportunities for care teams to better support patients throughout their journey.  In partnership with HOPA and APSHO. This program was made possible with support from Johnson & Johnson and Genentech. Guest:  Leslie Mader, RN, BSN, OCN  Patient Care Coordinator, Bispecific Drug Therapy and IEC Therapy, Hematology/Stem Cell Transplant  Vanderbilt Ingram Cancer Center "It decreased the amount of time they had to be in the clinic, you know, because a lot of these people we're getting them back to their regular lives where they can work, they can go to you know continue on with life. So anything that we can give that's in an injection, and anything that's targeted to decrease systemic reactions is better for the patient."  - Leslie Mader "They think, oh, this is great. I'm going to get through it with no problems. And then they get dose three or dose four, and they're like crap. You know, they get discouraged. But usually, you know, we have emergency drugs that we give them dexamethasone, and it usually resolves quickly."  - Lesie Mader Resources: A Blueprint for Successful Integration of Bispecific Antibodies   Delivery Models for Administering T-Cell-Engaging Bispecific Antibodies  Delivering T-Cell-Engaging Bispecific Antibodies: Frequently Asked Questions (FAQ) ACCC Office Hours Recording - Bispecific Antibodies: One BiTE at a Time     Bispecific Antibodies Checklist for Community Providers Using Bispecific Antibodies in Community Practice: Challenge and Opportunities Expanding Access to Cellular and Bispecific Therapies: Considerations and Recommendations   

In this episode of Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, was joined by Stephen V. Liu, MD, the division chief of Hematology Oncology at MedStar Georgetown University Hospital, part of the MedStar Georgetown Cancer Institute, in Washington, DC.Their discussion centered on the continued evolution of precision medicine in non–small cell lung cancer (NSCLC), highlighting advances in molecular testing, targeted therapies, immunotherapy, and emerging treatment strategies presented at the 2026 ASCO Annual Meeting. Drs Park and Liu explored how lung cancer has become a model for precision oncology and emphasized that therapeutic advances across multiple tumor types have collectively shaped the current treatment landscape. They discussed the importance of understanding oncogenic drivers, overcoming resistance mechanisms, and moving effective therapies into earlier-stage disease to improve long-term patient outcomes.

Coeliac disease is often viewed as a straightforward gastrointestinal condition, but its presentation, diagnosis and long-term management can be far more complex than many clinicians appreciate.In this episode of the RCP Medicine Podcast Dr. Dushen Murugiah, Consultant Gastroenterologist and Trust Lead for Nutrition at Royal Surrey County Hospital NHS Foundation Trust, joins Dr Abhishek Ray to explore the modern approach to coeliac disease.Together they discuss classical and non-classical presentations, the challenges of diagnosing an often under-recognised condition, the role of serology and small bowel biopsy, and the importance of considering celiac disease in patients presenting with unexplained anaemia, nutritional deficiencies and other extraintestinal manifestations. The conversation also explores refractory celiac disease, practical challenges associated with lifelong gluten avoidance, and promising future therapies currently under investigation.This episode offers practical, evidence-informed insights for physicians, trainees and healthcare professionals involved in the assessment and management of patients with suspected or confirmed coeliac disease.  Explore our CPD portfolio by your career stageEducation and professional developmentLeadership CPDTeach the teacherEducational supervisorSix-step programme RCP Social MediaInstagramLinkedInFacebookBlueskyMusic Ep 50 onward - Bensound.com  Ep 1 - 49 'Impressive Deals' - Nicolai Heidlas Any adverts within this podcast may use computer generated voices

Jimmy Chang, Chairman and CEO of TaiMed Biologics,  is approaching critical unmet needs in HIV care, particularly for aging patients with comorbidities who face risks from drug-drug interactions with multiple medications. The company is advancing the next-generation antibodies designed for bimonthly injections and an alternative to daily oral medications, while minimizing enzymatic metabolism and associated drug interactions. While successful treatments for HIV have shifted the focus from survival to quality of life and managing a chronic condition, new challenges have emerged to ensure patient convenience and adherence.  Jimmy explains, "TaiMed is a biotech company based in Taiwan. Our focus is to develop innovative product for the HIV. And actually, over the years we have developed the first CD4-directed antibody for HIV treatment, and the product was approved in the US. And today we are currently focusing on developing the CD4-targeting antibody in a combination for long-acting HIV treatment."   "So in today's world, HIV therapies, HIV patients, or the people living with HIV, the field is HIV as a chronic disease. The patient can live longer and healthier just like everybody else. However, it requires dedication and commitment to medication because there's no cure today. HIV, the virus keeps mutating. So if the disease is not under control, this could be problematic, and basically one day the patient may run into a situation where most of the drugs do not work for the patient." "So in the earlier days, the innovations or the medications were mainly trying to have the virus under control, with the focus of the medications. And so nowadays, because people living with HIV actually have a very good health condition, just like typical individuals live longer and healthier. So this comorbidity, or we call it the polypharmacy drug-drug interaction, is really the challenge that the physicians or patients have to face every day. And with our innovations, we believe we have the opportunity to offer another innovative medication to specifically address those challenges." #TaiMed #HIVCare #LongActingTherapies #AntibodyTherapeutics #CD4 #Polypharmacy #InfectiousDiseases #TaiMedBiologics #EmpoweredPatient #HealthcareInnovation taimedbiologics.com Download the transcript here 

Jimmy Chang, Chairman and CEO of TaiMed Biologics,  is approaching critical unmet needs in HIV care, particularly for aging patients with comorbidities who face risks from drug-drug interactions with multiple medications. The company is advancing the next-generation antibodies designed for bimonthly injections and an alternative to daily oral medications, while minimizing enzymatic metabolism and associated drug interactions. While successful treatments for HIV have shifted the focus from survival to quality of life and managing a chronic condition, new challenges have emerged to ensure patient convenience and adherence.  Jimmy explains, "TaiMed is a biotech company based in Taiwan. Our focus is to develop innovative product for the HIV. And actually, over the years we have developed the first CD4-directed antibody for HIV treatment, and the product was approved in the US. And today we are currently focusing on developing the CD4-targeting antibody in a combination for long-acting HIV treatment."   "So in today's world, HIV therapies, HIV patients, or the people living with HIV, the field is HIV as a chronic disease. The patient can live longer and healthier just like everybody else. However, it requires dedication and commitment to medication because there's no cure today. HIV, the virus keeps mutating. So if the disease is not under control, this could be problematic, and basically one day the patient may run into a situation where most of the drugs do not work for the patient." "So in the earlier days, the innovations or the medications were mainly trying to have the virus under control, with the focus of the medications. And so nowadays, because people living with HIV actually have a very good health condition, just like typical individuals live longer and healthier. So this comorbidity, or we call it the polypharmacy drug-drug interaction, is really the challenge that the physicians or patients have to face every day. And with our innovations, we believe we have the opportunity to offer another innovative medication to specifically address those challenges." #TaiMed #HIVCare #LongActingTherapies #AntibodyTherapeutics #CD4 #Polypharmacy #InfectiousDiseases #TaiMedBiologics #EmpoweredPatient #HealthcareInnovation taimedbiologics.com Listen to the podcast here 

In this podcast, 2 leading haematologists discuss the unmet needs in multiple myeloma in the second-line setting and beyond, considerations for treatment decisions, and the evolving treatment landscape with a focus on B-cell maturation antigen-targeted bispecific antibodies, a rapidly advancing class of treatments in this setting. This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the Advances in Therapy website and by using this link: https://link.springer.com/article/10.1007/s12325-026-03715-z. All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

Leon Tian, Director of US Project Management, ProBio, walked through the cell line development, high-concentration formulation, and purification workflow, delivering a bispecific antibody tox batch from a single selected clone in 4 to 5 months at CDMO Live Europe 2026.Speed is always a top priority in biologic CMC development — but most of the time, speed trades against quality or regulatory confidence. What I want to show today is that this trade-off is not necessary.”ProBio's client brought a demanding brief: a bispecific antibody project requiring a high-concentration formulation of approximately 120 mg/mL, produced from a single selected clone, with a tox batch delivered in 4 to 5 months. Tian called it a “mission impossible” scenario, then spent the session methodically explaining how ProBio's platform addresses each part of that challenge.Read the full article.

How can bispecific antibodies be safely delivered outside the hospital? Rahul Banerjee, MD and Ajay Nooka, MD discuss outpatient step-up dosing, prophylactic tocilizumab, CRS management, and practical tips for implementing bispecific therapy in academic and community practice.  

In this episode Editor-in-Chief Dr. Sadis Matalon (University of Alabama Birmingham) interviews author Dr. Sophia N. Karagiannis (King's College London) about the recently published Review article by Cheung et al. The authors review the latest research into antibody-drug conjugates (ADCs), referred to as “magic bullets” that kill cancer cells with minimal damage to healthy tissue. What are the main obstacles to manufacturing ADCs and can they be used to treat all types of cancer? Listen now to find out.   Anthony Cheung, Yi Liu, Alicia M. Chenoweth, Hanieh Montaseri, Benjamina Esapa, Vijay Chudasama, James R. Baker, David E. Thurston, and Sophia N. Karagiannis Antibody-drug conjugate design and mechanisms of action for cancer treatment: state of the art and beyond Physiological Reviews, published April 20, 2026. DOI: 10.1152/ physrev.00039.2025

Welcome to Fertility & Sterility Roundtable, hosted by Dr. Emily Barnard and Dr. Ben Peipert! Each week, we will host a discussion with the authors of "Views and Reviews" and "Fertile Battle" articles published in a recent issue of Fertility & Sterility.  Today, we will be discussing the Views and Reviews from the May 2026 edition of Fertility and Sterility entitled "Male Infertility and Immune Function."  This Views and Reviews brought together experts, some of whom we will be interviewing today, who evaluated and summarized the evidence on how the immune system plays a role in male fertility and infertility in general. We know that infertility is caused, at least in part, by a male component in about 50% of cases, and we are appreciative to our guests for joining us in discussion today. We encourage all of our listeners to read the full articles in the journal as we will not be able to cover all the content in this episode. Dr. Michael L. Eisenberg is a Professor of Urology and Obstetrics & Gynecology at the Stanford University School of Medicine.  He is the director of Men's Health at Stanford.  Dr. Eisenberg's NIH-funded laboratory seeks to understand the association between a man's reproductive, sexual, and overall health.  Dr. Marcelo Mass Lindenbaum is a clinical research fellow at the Cleveland Clinic Foundation, soon to be transitioning to his urology residency at Cleveland Clinic Akron General. His primary academic research focuses on male infertility and its relationship with the urologic microbiome, and infection risks associated with prosthetic surgery. Dr. Scott Lundy is a Staff Urologist and Surgeon Scientist at the Cleveland Clinic Foundation who specializes in male reproductive medicine, sexual dysfunction, and microsurgery. Beyond his clinical practice, Dr. Lundy leads significant research efforts, including establishing a multi-institutional consortium to advance the study and treatment of male infertility. View Fertility and Sterility at https://www.fertstert.org/  

In this episode, Dr Sara Ann Scott and Dr Syeda Saba Kareem discuss toxicities and the safe management of bispecific antibodies used in the treatment of RRMM to improve outcomes for patients, including: The incidence of cytokine release syndrome (CRS), along with the grading system, treatment strategies, and the role of tocilizumab Neurologic toxicities like the clinical manifestation of ICANS and the ICE scoring system used to help assign grading and appropriate treatment with dexamethasone, levetiracetam, and/or high-dose methylprednisolone Infection susceptibilities associated with BCMA-targeted bispecific antibodies and how this varies for GPRC5D-directed targets throughout therapy How to set up and maintain a REMS program Get access to all of our new podcasts by subscribing to the Decera Clinical Education Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters: Syeda Saba Kareem, PharmD, BCOP Clinical Pharmacy Supervisor Malignant Hematology Moffitt Cancer Center Tampa, Florida Sara A. Scott, PharmD, BCOP Clinical Pharmacy Specialist,  Multiple Myeloma Emory Winship Cancer Institute Atlanta, Georgia Link to full program: https://bit.ly/3RUyrMx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

On the latest episode of the Translating Proteomics podcast, Nautilus VP of Scientific Engagement and proteomics industry expert Sheri Wilcox joins hosts Parag Mallick and Andreas Huhmer for a thought-provoking discussion of their proteomics "hot takes.”Each “hot take” is a provocative opinion on a topic in proteomics. Specifically, they cover:Insufficient biological validation is one of the biggest problems in proteomics.Antibody validation remains a distributed, inconsistent, lab-by-lab responsibility, and this model for validation may not be sustainable going forward.AI cell models are overhyped.Check out the episode for deep explorations of each of these hot takes and their potential remedies.After listening, be sure to let us know whether you agree, disagree, or have your own hot take to share!

Highlights from the PER® CME activity "ADCs and Bispecific Antibodies Across Solid Tumors: Integrating New Targets, New Data, and New Decisions" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.In this podcast, experts William J. Gradishar, MD, FASCO, FACP; Rebecca Arend, MD, MSPH; Aaron Lisberg, MD; and Ulka Vaishampayan, MD, FASCO; discuss emerging antibody-drug conjugates and bispecific agents in lung, breast, endometrial, and prostate cancers, and how these agents may shift the therapeutic landscape in these disease.Earn CME credit by completing the full accredited activity (available through June 30, 2027): https://www.gotoper.com/courses/adcs-and-bispecific-antibodies-across-solid-tumors-integrating-new-targets-new-data-and-new-decisions-xqkuThis podcast, including the narration, was developed by PER® (Physicians' Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by an educational grant from BioNTech.This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

In this episode we speak with Alon Goren from UC San Diego about his work at the intersection of genomic technology development and chromatin biology. We discuss how his lab studies how the epigenome is regulated, how disruption of that regulation contributes to disease, and how technology can be improved to make results more robust and reproducible. We talk about his early interest in biology, how that developed through medical research training, and how a molecular biology lab shaped the direction of his career. He explains how curiosity about how cells and organisms work led him toward genomics and chromatin research. We then discuss several methods from his career, including early direct sequencing approaches for small amounts of DNA and RNA, ChIP-based methods for chromatin regulators, and work on improving ChIP-seq workflows. He explains why antibody choice matters, why monoclonal antibodies can improve reproducibility, and how automation helped scale the process. We also cover his work on spike-in normalization, including the risks of using exogenous chromatin incorrectly and the need for better safeguards in genome-wide comparisons. He describes a newer approach that uses two spike-ins to provide multiple checks on normalization. Finally, we discuss his work on short tandem repeats, zebrafish heart regeneration, and SIRT6-related polymerase pausing, as well as a newer platform that converts molecular interactions into sequencing-readable barcodes. He closes by stressing the importance of validation, careful protocol design, and methods that can be used reliably by multiple people. References Ram, O., Goren, A., Amit, I., Shoresh, N., Yosef, N., Ernst, J., Kellis, M., Gymrek, M., Issner, R., Coyne, M., Durham, T., Zhang, X., Donaghey, J., Epstein, C. B., Regev, A., & Bernstein, B. E. (2011). Combinatorial patterning of chromatin regulators uncovered by genome-wide location analysis in human cells. Cell, 147(7), 1628–1639. https://doi.org/10.1016/j.cell.2011.09.057 Busby, M., Xue, C., Li, C., Farjoun, Y., Gienger, E., Yofe, I., Gladden, A., Epstein, C. B., Cornett, E. M., Rothbart, S. B., Nusbaum, C., & Goren, A. (2016). Systematic comparison of monoclonal versus polyclonal antibodies for mapping histone modifications by ChIP-seq. Epigenetics & chromatin, 9, 49. https://doi.org/10.1186/s13072-016-0100-6 Patel, L. A., Cao, Y., Mendenhall, E. M., Benner, C., & Goren, A. (2024). The Wild West of spike-in normalization. Nature biotechnology, 42(9), 1343–1349. https://doi.org/10.1038/s41587-024-02377-y Ben-Yair, R., Butty, V. L., Busby, M., Qiu, Y., Levine, S. S., Goren, A., Boyer, L. A., Burns, C. G., & Burns, C. E. (2019). H3K27me3-mediated silencing of structural genes is required for zebrafish heart regeneration. Development (Cambridge, England), 146(19), dev178632. https://doi.org/10.1242/dev.178632 Patel, L., Cao, Y., Xu, T., Modolo, E., Dishon, T., Zhang, L., Mendenhall, E., Heinz, S., Simon, I., Benner, C., & Goren, A. (2025). Improved spike-in normalization clarifies the relationship between active histone modifications and transcription. Genomics. https://doi.org/10.1101/2025.11.25.690627 Xu, T., Wang, J., Shin, Y., Cao, Y., Zhang, L., Modolo, E., Dishon, T., Fisher, J., Norton, M., Fry, C. J., Farjoun, Y., Mendenhall, E., Heinz, S., Benner, C., & Goren, A. (2026). Multiplexed measurements of protein-protein interactions and protein abundance across cellular conditions using Prod&PQ-seq. Genomics. https://doi.org/10.64898/2026.01.01.697286 Related Episodes Taking ChIP from Yeast to ENCODE to Enable Genome-Wide Regulatory Protein Mapping (Peggy Farnham) Comparing CUT&Tag to ENCODE ChIP-Seq in Alzheimer's Disease Samples (Sarah Marzi) Chromatin Profiling: From ChIP to CUT&RUN, CUT&Tag and CUTAC (Steven Henikoff) Contact Epigenetics Podcast on Mastodon Epigenetics Podcast on Bluesky Dr. Stefan Dillinger on LinkedIn Active Motif on LinkedIn Active Motif on Bluesky Email: podcast@activemotif.com

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/HCN865. CME/MOC/AAPA credit will be available until July 1, 2027.Scaling New Heights in Lung and Breast Cancer Care: Harnessing the Power of Antibody–Drug Conjugates in Patients With Brain Metastases In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/HCN865. CME/MOC/AAPA credit will be available until July 1, 2027.Scaling New Heights in Lung and Breast Cancer Care: Harnessing the Power of Antibody–Drug Conjugates in Patients With Brain Metastases In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/HCN865. CME/MOC/AAPA credit will be available until July 1, 2027.Scaling New Heights in Lung and Breast Cancer Care: Harnessing the Power of Antibody–Drug Conjugates in Patients With Brain Metastases In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/HCN865. CME/MOC/AAPA credit will be available until July 1, 2027.Scaling New Heights in Lung and Breast Cancer Care: Harnessing the Power of Antibody–Drug Conjugates in Patients With Brain Metastases In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/HCN865. CME/MOC/AAPA credit will be available until July 1, 2027.Scaling New Heights in Lung and Breast Cancer Care: Harnessing the Power of Antibody–Drug Conjugates in Patients With Brain Metastases In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/HCN865. CME/MOC/AAPA credit will be available until July 1, 2027.Scaling New Heights in Lung and Breast Cancer Care: Harnessing the Power of Antibody–Drug Conjugates in Patients With Brain Metastases In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure information is available at the beginning of the video presentation.

We would love to hear from you! Please send us your comments here. --------Thank you for listening! Your support of Joni and Friends helps make this show possible. Joni and Friends envisions a world where every person with a disability finds hope, dignity, and their place in the body of Christ. Become part of the global movement today at www.joniandfriends.org. Find more encouragement on Instagram, TikTok, Facebook, and YouTube.

Current Lyme disease tests look for antibodies produced by the immune system in response to Borrelia burgdorferi bacteria transmitted to humans by infected blacklegged ticks. My guest today says, "The problem is that these antibodies don't have the right characteristics to be clinically useful". New research led by Tufts University School of Medicine suggests that a group of immune molecules called anti-lipid antibodies may address these shortcomings. Joining me today do discuss this problem and the potential solution is Peter Gwynne, Phd. Dr Gwynne is a research assistant professor at Tufts University School of Medicine and the senior author of the new paper published in the journal, Infection and Immunity.   Antiphospholipid antibodies in acute and post-treatment Lyme disease

You asked your doctor for help. You got your blood work. You were told everything is normal. And you walked out feeling more confused than when you walked in, because if nothing is wrong, why do you still feel terrible? In this episode, I'm walking you through every lab I use to uncover weight loss resistance, what I'm looking for on each one, and why your doctor and I can look at the exact same numbers and come to completely different conclusions.IN THIS EPISODE, YOU'LL LEARN:Why "your labs are normal" doesn't mean your body is functioning optimally, and the real difference between diagnosable and suboptimalWhy cutting calories below 1,500 when you're already weight loss resistant creates a brand new problem instead of a solutionWhat the DUTCH test shows us that a standard blood draw simply can't: what you're producing, how you're using it, and how you're detoxing itWhy the GI MAP is my favorite test of all, and why your gut is usually the environment your hormones are responding toThe energy conversion markers most women never get checked: vitamin D, a full iron panel, and B12Why a TSH alone is not a thyroid panel, and the five markers I want to see insteadThe blood sugar trio (fasting insulin, fasting glucose, hemoglobin A1C) and why fasting insulin is the one that tells the truthWhat an abnormal lipid panel in midlife is really telling you (hint: it's almost never your red meat)Why I don't put much weight on a normal CRP when your symptoms are telling a different storyTIMESTAMPS: 01:15 Welcome to Part 3: Getting the Data 02:05 Why Your Doctor Says "Normal" and I Say "Suboptimal" 04:17 When Eating Less Stops Working (And Starts Causing Harm) 06:34 Labs End the Guesswork Spiral 08:55 Data + Belief: Why Women Shift Fast When They Can See the Why 09:45 The DUTCH Test: Hormones, Cortisol Rhythm, and Detox Pathways 13:11 The GI MAP: Gut Lining, Digestive Capacity, and the Real Story on Pathogens 15:30 Vitamin D: The Hormone Pretending to Be a Vitamin 17:41 The Full Iron Panel: Your Energy Conversion Marker 19:37 Vitamin B12 and the Gut Absorption Connection 20:40 The Full Thyroid Panel: TSH, Free T4, Free T3, Reverse T3, and Antibodies 24:22 Fasting Insulin, Fasting Glucose, and Hemoglobin A1C 26:42 The Lipid Panel: It's Blood Sugar and Muscle, Not Your Eggs 27:50 CBC, CMP, and CRP: The Foundation Check 29:05 How the Midsummer Reset Targets Low-Grade Inflammation 30:51 You're Not Crazy, Lazy, or Lacking Discipline. This Is Data.RESOURCES:

Featuring perspectives from Prof Giuseppe Curigliano, Prof Rebecca A Dent, Dr Erika Hamilton, Prof Nadia Harbeck and Dr Hope S Rugo, moderated by Dr Rugo, including the following topics: Introduction (00:00) Evolving Role of Antibody-Drug Conjugates (ADCs) in the Management of Metastatic Triple-Negative Breast Cancer — Prof Dent (02:57) Integrating ADCs into the Management of HER2-Positive Metastatic Breast Cancer (mBC) — Prof Curigliano (29:01) Role of ADCs in the Management of Endocrine-Resistant Hormone Receptor-Positive mBC — Dr Rugo (52:36) Emerging Utility of ADCs for Localized Breast Cancer — Prof Harbeck (01:14:36) Tolerability Considerations with ADCs for Breast Cancer — Dr Hamilton (01:38:10) CME information and select publications

Featuring perspectives from Ms Courtney Arn, Ms Jamie Carroll, Dr Edward B Garon, Dr Heather McArthur and Dr Kathleen N Moore, moderated by Dr Moore, including the following topics: Introduction (0:00) Overview of Antibody-Drug Conjugates (ADCs) (2:07) Current and Future Role of HER2-Targeted ADCs for Breast Cancer (6:23) Currently Available ADCs for Gynecologic Cancer Management (26:37) Currently Available ADCs for Lung Cancer Management (44:07) Current and Future Role of TROP2-Targeted ADCs for Metastatic Breast Cancer (56:55) Other ADCs That May Soon Reach the Clinic for Advanced Gynecologic Cancers (1:15:07) Promising Investigational Strategies Employing ADCs for Lung Cancer (1:25:01) NCPD information and select publications  

This week on Tiny Show and Tell Us, a listener introduces us to "FARTs" — a silly acronym for galactic gas outflows — and sends us down a rabbit hole of dying stars and recycled cosmic gas in the early universe. Then we discuss the decades-long search for broadly neutralizing antibodies (bNAbs) that can target many HIV strains at once. One bNAb that looks promising is in clinical trials right now! We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

JHLT: The Podcast returns for July with a paper entitled "Comparing DSA-negative and DSA-positive antibody-mediated rejection in heart transplants: Results from the Trifecta-Heart study," available online now and in the July print issue of JHLT. Today's guests are first author Katelynn S. Madill-Thomsen, PhD and senior author Philip F. Halloran, MD, PhD, both from the Alberta Transplant Applied Genomics Center in Canada. In the episode, the authors and editors discuss: Striking similarities—and key differences—in the DSA-negative and DSA-positive groups Changes to clinical practice based on the findings, including innovations from the kidney transplant community Future studies, including tools and therapies that could be explored for improved clinical outcomes For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt. Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

Bringing home a new baby comes with so many questions, and feeding is often at the top of the list. In this solo episode, Dr. Carole Keim walks parents through the basics of newborn feeding with a reassuring message: fed is best. She explains what to expect during the first days of life, including how small a newborn's stomach really is, how breastfeeding develops over time, and why feeding can feel challenging in the beginning. Parents will learn about colostrum, milk production, feeding frequency, and how to recognize signs that their baby is getting enough to eat.  Dr. Keim also explores common breastfeeding challenges, practical tips for improving latch and milk supply, and the role of pumping, bottle feeding, donor milk, and formula. She discusses the benefits of breastfeeding while also emphasizing that there are many safe and healthy ways to nourish a baby. Whether you plan to breastfeed, formula feed, pump, or combine methods, this episode offers evidence-based guidance and encouragement to help you make feeding decisions with confidence during those important first weeks with your newborn.  Key Moments 00:00 Welcome and why “Fed is Best” matters 01:18 Why breastfeeding can be harder than expected 02:43 Newborn stomach size and feeding volumes by day 03:56 The first nights of feeding and newborn hunger patterns 05:03 Pumping, storing colostrum, and building milk supply 06:19 Benefits of breastfeeding for moms and babies 10:33 Breastfeeding recommendations and realistic feeding choices 14:35 Latch basics and breastfeeding troubleshooting 18:37 Pacifiers, nipple care, and knowing if baby is getting enough 22:41 Tongue ties, milk supply tips, and common breastfeeding concerns 31:36 Bottle feeding, formula options, and choosing the right formula 39:21 Final encouragement: nourishing your baby with confidence __ Why Breastfeeding Matters  Benefits for Baby Nutrition tailored to infant needs Antibodies and immune protection Lower risk of ear infections, diarrhea, and some respiratory illnesses Lower risk of SIDS Possible long-term reduction in obesity and diabetes risk Benefits for Parent Uterine recovery after birth Reduced postpartum bleeding Convenience and lower cost Possible reduction in breast and ovarian cancer risk Positioning and Latch Basics  Good Positioning Baby's ear, shoulder, and hip aligned Baby brought to breast, not breast to baby Nose to nipple alignment Signs of a Good Latch Wide-open mouth Lips flanged outward Deep latch, not shallow nipple sucking Rhythmic suck/swallow pattern Signs of Poor Latch Significant pain Clicking Cracked nipples Baby still hungry after long feeds How to Know Baby Is Getting Enough Milk Signs Wet diapers and stools Weight trends Swallowing sounds Baby seeming satisfied after many feeds Typical Expectations Initial weight loss can be normal Pediatric follow-up is important in the first days after discharge Red Flags Poor urine output Lethargy Persistent jaundice Dehydration signs When to Seek Help  Lactation Support Lactation consultants Pediatricians Family physicians Midwives Postpartum nurses Urgent Reasons to Seek Care Baby not waking to feed Fever Signs of dehydration Severe maternal breast pain/redness/fever Poor weight gain Giving bottles of formula How to choose regular, preemie, soy, anti-reflux, sensitive, hydrolyzed, goat, organic How to mix Follow the instructions on package closely Do NOT make your own infant formula; use one that is commercially available Mix with clean water; doesn't need to be distilled or boiled Any temp is ok; aim for cool to room temperature when you feed baby  Can mix up to 1 day worth at a time in the fridge Used bottles need to be finished within 2 hours or thrown away; can't be put back in the fridge Check out The Baby Manual on Amazon.  It will give you peace of mind when your new baby arrives.   __  Resources discussed in this episode: The Holistic Mamas Handbook is available on Amazon The Baby Manual is also available on Amazon __ Contact Dr. Carole Keim MD Website: CaroleKeim.com Linktree TikTok Instagram ---FullScript VitaminsUse this link to get 10% off and free shipping for orders over $50.HIRO DiapersUse code DRCAROLEKEIM for a discount at checkout. Click here. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

“Narrative remains a pretty unbeatable delivery device for information.” — Patrick Radden Keefe Has London really fallen? That's the question Patrick Radden Keefe — staff writer at The New Yorker and bestselling author of Empire of Pain and Say Nothing — addressed in his new book, London Falling: A Mysterious Death in a Gilded City and a Family's Search for Truth. One thing for sure is that Keefe himself hasn't fallen. He's been surprised by the book's success. “I thought the antibodies would get up because I'm an interloper,” the American confesses about writing about Britain. Antibodies or not, the book has been a #1 bestseller in both the UK and US. And we can look forward to an A24 and Brightstar TV adaptation soon. On London, the story is murkier. London Falling begins on November 29, 2019, when nineteen-year-old Zac Brettler falls to his death from a luxury apartment above the Thames. Every parent's ultimate nightmare. As it happens, I've known Zac's dad, Matthew, for many years. But what appeared to be a tragic accident or a suicide turned out to be something far more sinister — a story of double lives, dirty money, a dishonest businessman named Akbar Shamji, and a terrifyingly violent gangster known as Indian Dave. Lurking behind the Brettler death is what Keefe presents as the greatest deceit of all — London's cruel descent into what he sees as the moneyed miasma of post-Thatcherite neo-liberalism. London is, in Keefe's compelling narrative, the most invisible of cities — where power lies with criminals like Indian Dave, where the police are at best bystanders, and where a teenage fantasist from a comfortable middle-class family can become fatally entangled in a fallen world he barely understood. Five Takeaways •       Zac Brettler: The Double Life That Led to His Death: Zac Brettler was nineteen years old. He fell — or was pushed, or was forced to jump — from a luxury apartment balcony above the Thames on November 29, 2019. He had been living a double life: to London's criminal underworld, he was Zac Ismailov, the son of a Russian oligarch, heir to a great fortune. He had even fabricated bank statements showing a personal account holding $1 million. Under this guise, he became entangled with Akbar Shamji, a slippery businessman, and a man known as Indian Dave, a violent extortionist. Keefe's reporting suggests Zac jumped to escape from one of these men. Scotland Yard's passivity in investigating the case is, in Keefe's word, bizarre. •       London as a Twenty-Four-Hour Laundromat for Dirty Money: Keefe's portrait of London is the book's macro argument: a global city that has been hollowed out by decades of financial deregulation, whose financial sector is stacked with professional facilitators eager to help protect or conceal a dubious fortune, where posh mansions and private nightclubs serve as the visible surface of a hidden economy of criminal money. Zac Brettler was not rich. He was a boy from a comfortably off family who became fixated on the glitzy, mercenary, aspirational culture embodied by foreign billionaires who had bought mansions and football clubs in his city. London, in Keefe's telling, did this to him. •       The Brettlers' Consent: A Long Haul With the Family: Keefe had written 15,000 words for The New Yorker when he knew there was a book. He went to Matthew and Rochelle Brettler and their surviving son Joe and told them: I will only do this with your blessing. They read the finished piece, talked amongst themselves, and came back with a yes. Keefe's method: he is an open book; he invites sources to read his previous work. It took him an LSE graduate who became one of the most trusted journalists in the world to persuade a devastated family to trust him with their son's story. They made the right decision. •       Narrative as Delivery Device: Keefe's Method: Keefe on why he writes the way he writes: everyone has a phone in their pocket making claims on their attention. Narrative — true stories about real people, told with enough seductive propulsive energy — remains the most powerful way to convey information, to make someone who would not otherwise read nonfiction want to keep turning pages. He is looking, always, for inherently dramatic stories. London Falling is that: a whodunit, a parental love story, a portrait of a corrupted city, and a thriller, all in one book. The New York Times described the whole book as one of the best of 2026 so far. •       The Television Adaptation: A24, Brightstar, and the Lessons of Say Nothing: A24 and Brightstar are producing the television adaptation of London Falling. Five production companies had to audition for the Brettlers over Zoom. The family is involved. Keefe knows from Say Nothing — which took five years from book to screen and won awards as an FX series — that this cannot go on autopilot. The aim: something sophisticated, sensitive, and just to the family's story. The first word on the Mill Hill School website is “integrity.” Whether that word will survive contact with a television adaptation remains to be seen. About the Guest Patrick Radden Keefe is a staff writer at The New Yorker and the author of London Falling: A Mysterious Death in a Gilded City and a Family's Search for Truth (Doubleday, April 7, 2026; #1 New York Times bestseller), Empire of Pain: The Secret History of the Sackler Dynasty (winner of the Baillie Gifford Prize), Say Nothing: A True Story of Murder and Memory in Northern Ireland (National Book Critics Circle Award; named one of the twenty best books of the 21st century by the New York Times), Rogues, and Chatter. He is the recipient of a Guggenheim Fellowship, the National Magazine Award, and the Orwell Prize. He served as executive producer on the award-winning FX series Say Nothing and is the creator and host of the podcast Wind of Change. References: •       London Falling: A Mysterious Death in a Gilded City and a Family's Search for Truth by Patrick Radden Keefe (Doubleday, April 7, 2026). •       Empire of Pain: The Secret History of the Sackler Dynasty by Patrick Radden Keefe — referenced at the opening. •       Say Nothing (FX series, executive produced by Keefe) — referenced in the closing section. •       Andrew O'Hagan, Caledonian Road — referenced as covering similar London territory in fiction. •       A24 and Brightstar — the production companies making the London Falling television adaptatio...

Most GPCR antibody failures are silent. The signal looks clean, the band is there, the experiment moves forward - until someone runs a knockout control and the signal is still there. Lin and Ball have spent years building reagents for exactly this problem, and this conversation gets into the details of what reliable GPCR antibody characterization actually requires.Chia-Yi Lin and Alexander Ball are scientists-turned-industry professionals at GeneTex, a company that has shifted its entire new antibody production to recombinant monoclonal technology since 2019. In this conversation, they trace the arc from GeneTex's founding by cancer biology researchers in 1990s Texas to its current position as a growing source of characterized GPCR research reagents. The discussion covers why GPCR targets are especially difficult immunogen design problems, what five-pillar antibody characterization looks like for receptors like LGR5 and the chemokine receptor family, and why the word "characterized" may be more scientifically honest than "validated" when describing what an antibody data sheet actually tells you. Ball's path from medicine to the bench to industry - and Lin's from stem cell biology to leading international operations at GeneTex - brings a rare dual perspective to a problem that most researchers only see from one side.Key topics covered:Why GPCR family homology - including the 75% sequence identity between CXCR1 and CXCR2 - makes immunogen selection the critical upstream decision in antibody development, often determining success or failure before a single experiment is runWhat five-pillar characterization looks like in practice: KO and KD validation, comparable antibody testing, cell fractionation, tissue orthogonal testing, and GPCR virion arrays from CDI LabsHow recombinant monoclonal antibodies solve the batch variability problem that polyclonal production cannot - and why a sequence defined in a plasmid changes reproducibility for the entire fieldThe LGR5 story: how one leucine-rich repeat GPCR critical to intestinal stem cell biology became GeneTex's defining early challenge - and why Ball's company president went pale when the target came upWhy Ball and Lin encourage researchers to contact the company directly before purchasing, what questions to ask, and how a free GPCR antibody sample program is actively connecting the community with reagents that need real-system testingDr. GPCR Links and ResourcesDr. GPCR Ecosystem: https://www.ecosystem.drgpcr.com/Membership and Pricing: https://www.ecosystem.drgpcr.com/university-pricingWeekly News: https://www.ecosystem.drgpcr.com/gpcr-weekly-news

On this episode of The Federalist Radio Hour, Dr. Mary Talley Bowden, a Houston-based ear, nose, throat, and sleep medicine specialist, joins Federalist Elections Correspondent Matt Kittle to discuss her ongoing fight against the healthcare complex, its campaign to push a dangerous Covid-19 shot over other effective treatments, and the widespread effort to silence dissenting voices. You can buy Dr. Bowden's new book, Dangerous Misinformation: The Virus, the Treatments, and the Lies here.The Federalist Foundation is a nonprofit, and we depend entirely on our listeners and readers — not corporations. If you value fearless, independent journalism, please consider a tax-deductible gift today at TheFederalist.com/donate. Your support keeps us going.

Most people with elevated thyroid antibodies are told, “Don't worry, your thyroid is fine.” But what does the research actually say?In this episode of Reversing Hashimoto's, Dr. Anshul Gupta explores the hidden impact of thyroid antibodies, including their connection to thyroid tissue destruction, infertility, miscarriage, hormonal imbalances, brain fog, autoimmune disease, and long-term health risks. Learn why normal TSH levels don't always mean optimal thyroid health, how thyroid antibodies affect the entire body, and what current research reveals about their significance.Dr. Gupta also shares practical strategies for lowering thyroid antibodies and a real patient success story that demonstrates what's possible when the root causes of autoimmune thyroid disease are addressed.If you've been told your antibodies don't matter, this episode may change the way you think about your thyroid health.

Bispecific antibodies (BsAbs) are an emerging and fast-developing area of immunotherapy, particularly in the treatment of hematologic malignancies. However, access to this therapy remains limited, particularly for Veterans. Administrative hurdles and challenging adverse events have slowed adoption of BsAbs in the US Department of Veterans Affairs (VA). In this episode, CANCER BUZZ speaks with Nicholas Burwick, MD, hematologist in the Puget Sound VA Health Care System, about how his VA site tackled these challenges and made BsAbs available to its patient population through a collaborative hub-and-spoke model.  Guest: Nicholas Burwick, MD President, Association of VA Hematology/Oncology Hematology and Bone Marrow Transplant Puget Sound VA Health Care System "We set expectations, we came up with a plan, and we didn't have too many bispecific antibody patients at the same time. At least initially, we wanted some control." — Nicholas Burwick, MD  "The collaboration among different VA centers has been something that I've come to appreciate. We have a heme malignancy group, for example, so we can compare notes, work together, and in some cases even collaborate on VA initiative proposals or industry-sponsored clinical trials." — Nicholas Burwick, MD Resources: Addressing Care Disparities for Veterans: Tackling Barriers and Identifying Solutions Bispecific Antibodies Bispecific Antibodies Are Moving Forward; So Are the Implementation Questions Service, Sacrifice, and Survival: Advancing Cancer Care for America's Heroes  

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant advancements shaping the landscape of our industry. As technology continues to redefine traditional paradigms, the collaboration between Pfizer and Chai Discovery exemplifies this trend. By harnessing artificial intelligence, particularly through custom models like Chai-3, this partnership aims to revolutionize drug discovery. The integration of AI promises not only to accelerate the identification of biologics and antibodies but also to optimize resource allocation in research and development. Such technological integration could pave the way for an enhanced pipeline of innovative treatments, marking a transformative shift in how therapeutic candidates are developed. In the realm of regulatory developments, Lupin's Ranluspec has recently received FDA approval as an interchangeable biosimilar targeting VEGF-A for various retinal conditions. This move underscores the importance of biosimilars in providing cost-effective alternatives to expensive biologics, thereby expanding patient access to essential treatments for conditions like macular degeneration. Additionally, the MHRA's marketing authorization for Aujemflu, an adjuvanted trivalent influenza vaccine for adults aged 50 and over, reflects ongoing efforts to bolster protection against infectious diseases among vulnerable populations. Clinical trial advancements continue to highlight significant progress in therapeutic development. Otsuka Pharmaceuticals' Phase 3 data on Voyxact has shown promising stabilization of kidney function in patients with Immunoglobulin A nephropathy. This protein therapy targets autoimmune pathways, offering new hope for managing this chronic kidney condition. Similarly, Autobahn Therapeutics' Elunetirom has advanced to a pivotal trial following Phase 2 success in treating bipolar depression. This showcases the potential of small molecule therapies targeting thyroid hormone receptors. Meanwhile, Hikma Pharmaceuticals' victory in a landmark patent case regarding skinny labels marks an important development in pharmaceutical intellectual property rights. The unanimous Supreme Court ruling against Amarin supports the legitimacy of using skinny labels to market generic versions of drugs for non-patented indications. This decision could enhance market competition and drive down healthcare costs, setting a precedent for future intellectual property disputes. On the business front, strategic partnerships and mergers continue to shape industry dynamics. Gilead Sciences' acquisition of Ouro Medicines for $1.675 billion strengthens its autoimmune inflammation pipeline. This transaction exemplifies how major deals are reshaping therapeutic portfolios in response to growing demand for treatments targeting rare diseases. Financially, Solix Pharmaceuticals' success in raising $71 million to advance its siRNA pipeline across multiple therapeutic areas demonstrates investor confidence in RNA-based therapeutics as a promising frontier for innovative treatments. Conversely, challenges persist as evidenced by Takeda's $2.5 billion legal provision over an antitrust case related to Amitiza, underscoring ongoing financial risks associated with litigation in the pharmaceutical sector. Corporate restructuring also signals shifts within the industry landscape. Fulcrum Therapeutics' decision to lay off 85% of its workforce following the discontinuation of its sickle cell disease candidate highlights the volatility and high stakes inherent in drug development. Overall, these developments illustrate a dynamic landscape where scientific innovation is propelled by AI-driven approaches and strategic collaborations while regulatory victories and financial maneuvers shape market dynamics. These trends have profound implications for patient care by potentially accelerating the availability of novel therapies and fostering a competitive environment that drives down costs. As we look ahead, stakeholders must navigate these complexities effectively to harness opportunities and address challenges within this rapidly evolving industry landscape. The ability to adapt and capitalize on emerging trends will be crucial as these sectors continue to evolve, ultimately enhancing patient care and advancing therapeutic frontiers globally. Thank you for joining us today on Pharma Daily; stay tuned for more insights into the ever-changing world of pharmaceuticals and biotech.Support the show

Featuring perspectives from Prof Ramez Eskander and Dr Bradley Monk, moderated by Dr Kathleen Moore, including the following topics: Introduction (0:00) Advances in Human Cadherin-6-Targeted Antibody-Drug Conjugates (ADCs) in Ovarian and Other Gynecologic Cancers — Dr Moore (1:30) Leveraging TROP2-Directed ADCs in Advanced Gynecologic Cancers — Prof Eskander (35:39) Tolerability and Other Practical Considerations with Novel Investigational ADCs in Advanced Gynecologic Cancers — Dr Monk (1:04:58) CME information and select publications

T-cell-engaging bispecific antibodies represent a major therapeutic and scientific advancement in the treatment of several types of cancer. However, they carry a risk of some unique acute toxicities, such as cytokine release syndrome and neurologic toxicity. This podcast reviews this emerging drug class and strategies for recognition and management of their unique adverse events. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

From Discovery to Delivery: Charting Progress in Gynecologic Oncology, hosted by Ursula A. Matulonis, MD, brings expert insights into the most recent breakthroughs, evolving standards, and emerging therapies across gynecologic cancers. Dr Matulonis is chief of the Division of Gynecologic Oncology and the Brock-Wilson Family Chair at the Dana-Farber Cancer Institute, as well as a professor of medicine at Harvard Medical School, both in Boston, Massachusetts.In this episode, Dr Matulonis was joined by Meghan E. Shea, MD, an attending medical oncologist and ambulatory medical director and disease program leader for medical oncology at Beth Israel Deaconess Medical Center in Boston. Together, they explored the current landscape of cervical cancer, from the urgent need for expanded vaccination and screening to the evolving role of immunotherapy and antibody-drug conjugates (ADCs) across disease settings.Dr Shea opened by addressing the epidemiology of cervical cancer, noting that despite decades of progress, rates are now plateauing and rising among women under 50 years of age. She identified 3 interrelated drivers of this trend: declining rates of routine gynecologic screening, inconsistent uptake of human papillomavirus (HPV) vaccination, and persistent high-risk HPV infections, particularly HPV 16 and 18, which are responsible for most cases. The conversation then turned to the effect of immunotherapy on cervical cancer treatment. Dr Shea traced the evolution of pembrolizumab (Keytruda) from its initial 2018 approval as a single agent in recurrent/metastatic disease to its more recent integration into the frontline setting. The phase 3 KEYNOTE-A18 trial (NCT04221945) demonstrated that adding pembrolizumab to standard weekly cisplatin-based chemoradiation significantly improved outcomes for patients with locally advanced disease. Although responses to immunotherapy, when they occur, are often durable, Dr Shea acknowledged that response rates remain lower than anticipated for a virally driven malignancy, underscoring the need for novel combinations and a deeper understanding of resistance mechanisms. Drs Matulonis and Shea both agreed that immunotherapy combined with ADCs represents one of the most compelling directions for the field, with phase 2 data for sacituzumab tirumotecan plus pembrolizumab generating interest ahead of anticipated phase 3 results.On the ADC front, Dr Shea reviewed the 2 agents in this class that are currently FDA-approved for cervical cancer. Tisotumab vedotin-tftv (Tivdak) offers the advantage of biomarker-independent use, though its requirement for ophthalmologic monitoring at every treatment visit creates real-world access challenges outside major academic centers. Trastuzumab deruxtecan-nxki (Enhertu), approved in the HER2 immunohistochemistry 3+ setting based in part on the results of the phase 2 DESTINY-PanTumor02 trial (NCT04482309), has generated robust response rates but is most likely to benefit patients with adenocarcinoma. Dr Shea also highlighted additional targets under investigation, including Trop-2, Nectin-4, and B7-H4, with multiple phase 3 trials ongoing in both the frontline and recurrent settings.The discussion closed with a look at the locally advanced disease landscape, where the NRG Oncology cooperative group is conducting a phase 3 trial to evaluate whether integrating the neoadjuvant carboplatin/paclitaxel regimen from the INTERLACE trial (NCT01566240) with the pembrolizumab-based regimen from KEYNOTE-A18 can further improve outcomes and reduce the morbidity associated with brachytherapy. Dr Shea expressed optimism about this question, citing preliminary experience suggesting that neoadjuvant chemotherapy may reduce the need for invasive radiation techniques.

The conversation covers the understanding of Hashimoto's Thyroiditis, the role of the immune system, the impact of iodine, management with diet and supplements, antibody levels, natural auto antibodies, immune system shift, calming the immune system, and the conclusion.TakeawaysUnderstanding the role of the immune system in Hashimoto'sManaging Hashimoto's with diet and supplementsChapters00:00 Understanding Hashimoto's Thyroiditis05:17 The Immune System and Antigens10:24 Understanding Antibody Levels in Hashimoto's

Welcome to the Oncology Brothers podcast! In this episode, we dived deep into the world of bispecific antibodies approved for multiple myeloma. Joined by myeloma specialists Dr. Hamza Hashmi from Memorial Sloan Kettering and Dr. Cesar Rodriguez from Mount Sinai, they discussed the latest updates, clinical pearls, and practical insights for community oncologists. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Key topics included: Overview of bispecific antibodies, focusing on GPRC5D and BCMA-targeted therapies. Detailed discussion on talquetamab, teclistamab, elranatamab, and linvoseltamab, including dosing, side effects, and management strategies. Insights on managing cytokine release syndrome (CRS), neurotoxicity, and other side effects like dysgeusia, skin toxicity, and infections. Prophylactic measures, including the use of IVIG and tocilizumab, to enhance patient care and quality of life. Whether you're a healthcare professional or simply interested in the latest advancements in cancer treatment, this episode is packed with valuable information. Don't forget to like, subscribe, and check out our other episodes for more insights into oncology! #MultipleMyeloma, #BispecificAntibody, #ICANS, #CRSmanagement, #OncologyBrothers

Save your seat in the free Thyroid and Hormone class https://fixyourthyroid.com/natalie  If you are a woman in midlife who has been told everything is fine when you know in your body that something is NOT fine, this episode is going to change everything. I have Dr. Amie Hornaman, The Thyroid Fixer, back on the show, and we are going somewhere we have never gone before. One in eight women will develop a thyroid condition in her lifetime. Eighty-eight percent of us are metabolically unhealthy. And yet most doctors run ONE test, look at one number, tell us we are normal, and send us home with an antidepressant. Meanwhile we are gaining weight, losing our hair, can't sleep, can't think, can't lose a pound to save our lives, and being told it is just stress, just aging, just menopause. Today we are tearing that apart. Dr. Amie saw SEVEN doctors before she was finally diagnosed. She is now licensed to prescribe thyroid and bioidentical hormones in all 50 states and most of Canada. She built the Better Thyroid and Hormone Institute, hosts The Thyroid (and Hormone) Fixer Podcast, and has helped thousands of women globally finally get answers. We go DEEP on: Why the standard TSH-only test misses almost everyone, and the six tests you need to ask for by name THYROPAUSE: Dr. Amie's term for what happens when thyroid dysfunction collides with perimenopause and menopause (and why so many women are being treated for the wrong one) The T4-only medication trap: why Synthroid and levothyroxine fail an estimated 98% of patients Reverse T3, the silent saboteur that blocks your active thyroid hormone from getting into your cells Natural desiccated thyroid, the controversy, FDA scrutiny of animal-derived medications, and where Dr. Amie stands T2: the FORGOTTEN thyroid hormone with 30+ years of research that burns fat at the mitochondrial level, does not suppress your own thyroid, does not jack up your heart rate, does not require a prescription, and is showing up in studies as a potential anti-obesity treatment What Ozempic, Wegovy, and Mounjaro are actually doing to your thyroid (and why some women lose ZERO weight on GLP-1s no matter how high they push the dose) The estrogen, progesterone, testosterone, cortisol, and insulin connection: why you cannot fix the thyroid without addressing the whole hormonal system Antibody-support strategies: gluten elimination, black cumin seed oil, low-dose naltrexone, and thymosin alpha Iodine titration cautions, medical gaslighting, and what to say when your doctor refuses to run the full panel The Monday morning action plan: exactly what to do this week if you suspect your thyroid is the missing piece This is not a thyroid 101 episode. This is the conversation I wish every midlife woman was given the day her labs came back normal. You are not broken. You are not crazy. And you are not alone. Sign up for the free Thyroid and Hormone class https://fixyourthyroid.com/natalie    Connect with Dr. Amie: Podcast: The Thyroid (and Hormone) Fixer Instagram: @dramiehornaman Book: https://thyroidfixbook.com/ Live lab-review class https://fixyourthyroid.com/natalie  Better Thyroid and Hormone Institute: dramiehornaman.com   APPROXIMATE TIMESTAMPS: 00:00 — The medical gaslighting that is keeping midlife women sick 06:00 — The full thyroid panel: the six tests to ask for by name 12:00 — Introducing THYROPAUSE: where thyroid meets menopause 20:00 — How estrogen, progesterone, testosterone, and cortisol all impact your thyroid 28:00 — Why T4-only medication (Synthroid, levothyroxine) fails 98% of patients 34:00 — Natural desiccated thyroid, FDA scrutiny, and individualized dosing 40:00 — T2: the forgotten thyroid hormone that burns fat without touching your gland 48:00 — Who should consider T2 (and why it does not require a prescription) 52:00 — What Ozempic and the GLP-1s are actually doing to your thyroid 58:00 — How to protect your thyroid if you are currently on a GLP-1 62:00 — Lifestyle non-negotiables: morning sun, protein, resistance training, sleep, blood sugar 67:00 — Your Monday morning action plan if you suspect your thyroid is the missing piece   Catch the full episode on YOUTUBE HERE: https://bit.ly/MidlifeConversationsYouTube   Learn More About Dr. Amie Hornaman  Instagram ➜ https://www.instagram.com/dramiehornaman Website ➜ https://fixyourthyroid.com/natalie      Thank you to our show sponsors:  MITOQ: Take control of healthy aging and longevity. Get 10% off using code NATALIEJILL at checkout on https://www.mitoq.com/  BIOPTIMIZERS: Get the digestive enzymes I take with every meal here https://www.bioptimizers.com/nataliejill Free Gifts for being a listener of Midlife Conversations! Mastering the Midlife Midsection Guide: https://theflatbellyguide.com/ Age Optimizing and Supplement Guide: https://ageoptimizer.com   Connect with me on social media! Instagram: www.Instagram.com/Nataliejllfit Facebook: www.Facebook.com/Nataliejillfit   For advertising inquiries: https://www.category3.ca/  Disclaimer: Information provided in the Midlife Conversations podcast is for informational purposes only. This information is NOT intended as a substitute for the advice provided by your physician or other healthcare professional. Do not use the information provided in this podcast for diagnosing or treating a health problem or disease, or prescribing medication or other treatment. Always speak with your physician or other healthcare professional before making any changes to your current regimen.  Information provided in this podcast and the use of any products or services related to this podcast does not create a client-patient relationship between you and the host of Midlife Conversations or you and any doctor or provider interviewed and featured on this show. Information and statements may have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent ANY disease. Advertising Disclosure: Some episodes of Midlife Conversations may be sponsored by products or services discussed during the show. The host may receive compensation for such advertisements or if you purchase products through affiliate links. Opinions expressed about products or services are those of the host and/or guests and do not necessarily reflect the views of any sponsor. Sponsorship does not imply endorsement of any product or service by healthcare professionals featured on this podcast.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Wyatt McDonnell, Ph.D., cofounder and CEO at Infinimmune, talks about how single-cell biology and computational rigor led to the formation of Infinimmune, and a new way to discover human-derived antibody drugs. Wyatt explains Infinimmune's 'discovered in humans' antibody discovery platform, how the company was launched and initially funded, and how Infinimmune landed a Merck collaboration worth up to $838 million. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.  Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

In the second part of this series, Dr. Justin Abbatemarco and Dr. Paulus Rommer discuss how to apply these study results into clinical practice.  Show citation:  Vietzen H, Kühner LM, Berger SM, et al. Epstein-Barr Virus Antibodies to Differentiate Multiple Sclerosis From Other Neuroinflammatory Diseases. JAMA Neurol. Published online March 9, 2026. doi:10.1001/jamaneurol.2026.0240  Show transcript: Dr. Justin Abbatemarco: Hello and welcome back. This is Justin Abbatemarco, and we're finishing up our interview with Paulus Rommer on his article on JAMA Neurology, Epstein-Barr Virus Antibodies that differentiate multiple sclerosis from other Neuroinflammatory Diseases. Paulus, can we talk about how we would apply your results into clinical practice right now? Dr. Paulus Rommer: The persistent high apnea antibody responses are a hallmark of multiple sclerosis. And in our micro center study, we found that the singular measurement is not sufficient to differentiate multiple sclerosis from other related disorders like MOGAD or NMOSD, but it's the repeated high levels over time. We see them in about 95% of our MS patients, but really rarely in MOGAD or NMOSD. So this persistent high levels is a good factor, with a high accuracy, to really diagnose multiple sclerosis and to differentiate them from MOGOD or NMOSD. Dr. Justin Abbatemarco: I think these are really helpful and I think a little more evolution in how we interpret these on individual patient level, like we talked about in the podcast, but more to come. Paulus, thank you again for all your work on this topic for coming on and we're excited to have you back in the future. Dr. Paulus Rommer: Thank you.   

Dr. Justin Abbatemarco talks with Dr. Paulus Rommer about the evolving understanding of Epstein-Barr virus (EBV) and its role in multiple sclerosis (MS), including recent research on EBV antibodies as diagnostic markers and potential therapeutic targets.  Read the related article in JAMA Neurology.  Disclosures can be found at Neurology.org. 

Dr. Alex Marson, MD, PhD, is a professor of medicine at the University of California, San Francisco. We discuss the biology of the immune system and cancer, and everyday choices that can increase or decrease your cancer risk, several of which are surprising but all of which are actionable. We also discuss immunotherapy, including how engineered T-cells can be used to defeat childhood and adult cancers. Dr. Marson explains CRISPR and gene editing to cure diseases, and we address the ethical questions surrounding gene editing in embryos, children and adults. This discussion is for anyone interested in avoiding cancer and/or seeking to understand the science and practical applications of immune- or gene-therapy. Read the show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman BetterHelp: https://betterhelp.com/huberman Helix Sleep: https://helixsleep.com/huberman LMNT: https://drinklmnt.com/huberman Function: https://functionhealth.com/huberman Timestamps (00:00:00) Alex Marson (00:02:21) Diseases & Current Biological Landscape; AI & Computational Tools (00:05:56) Immune System, Innate vs Adaptive Immune System (00:10:55) Thymus, T Cell Selection; B Cells & Antibodies (00:13:23) Sponsors: BetterHelp & Helix Sleep (00:16:11) Immune System Health, Sleep, Diet; Genes (00:20:56) Childhood Exposure & Allergy Prevention; Autoimmune Reactions (00:25:27) Whole Body Immune Response, Cytokines & Fever; Antibiotics (00:30:51) Cancer; Mutations & Cell Regulation; Smoking, BRCA Mutations, Sunlight (00:38:27) BRAC Mutations, Mutagens, Pesticides (00:42:33) Sponsor: AG1 (00:43:57) X-Rays & Airport Scanners, Carcinogen vs Mutagen, Charred Meat, Food Dye (00:49:34) Immune-Based Cancer Treatment, Checkpoint Inhibitors, CAR T-Cell Therapy (00:59:04) CRISPR, Immunotherapies (01:02:52) Age & Cancer Risk; CAR T-Cells, Targets & Side Effects; Ketogenic Diet (01:08:27) CRISPR Discovery & Mechanism (01:17:06) CRISPR Precision, Risk & Benefit; CRISPR Technology Evolution (01:20:57) Sponsor: LMNT (01:22:17) CRISPR Cell Delivery, Clinical Trials; Treating Early Cancers & Prevention (01:33:47) Liposomes, Engineered Viruses, Lipid Nanoparticles (LNPs), Vaccines (01:39:57) COVID Pandemic & Trust in Science, mRNA Vaccine (01:47:51) Sponsor: Function (01:49:39) Drug Delivery to Cancer, Immunotoxins, T-Cell Engagers; AI Protein Targets (01:55:45) CRISPR Embryo Modification, Ethics; Heritable Gene Editing, Diversity (02:05:42) Deep Sequencing Embryos, Diversity; Overcoming Adversity & Resilience (02:10:44) Upcoming Therapeutics, Autoimmunity & CAR T-Cells, CRISPR & Gene Function (02:17:55) Banking T Cells or iPSCs?, Future of Cell Programming (02:24:41) Zero-Cost Support, YouTube, Spotify & Apple Follow, Reviews & Feedback, Sponsors, Protocols Book, Social Media, Neural Network Newsletter Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices